每周一次司美格鲁肽用于HIV相关脂肪增生:一项随机、双盲、安慰剂对照2b期单中心临床试验
这项在美国单中心开展的随机双盲安慰剂对照2b期试验纳入108例HIV相关脂肪增生的成人,1:1接受每周皮下司美格鲁肽(8周剂量滴定后1.0 mg用24周)或安慰剂共32周。司美格鲁肽使腹部内脏脂肪面积显著下降(β -30.82 cm2,95%CI -50.13至-11.51;变化百分比-30.6%),但需在大规模试验中进一步审视严重不良事件风险。
要点
- 司美格鲁肽32周使腹部内脏脂肪面积变化百分比为-30.6%(β -30.82 cm2,95%CI -50.13至-11.51)。
- 腹部皮下脂肪变化百分比-11.2%,全身脂肪变化百分比-18.9%。
- 可能相关或相关不良事件的绝对风险差异为0.1111(95%CI -0.0727至0.2869),无统计学显著差异。
核心结论
- 司美格鲁肽有望成为HIV相关脂肪增生的有效治疗,但严重不良事件的潜在风险需在HIV感染者的大规模试验中进一步审视。
研究设计与样本
- 随机、双盲、安慰剂对照2b期临床试验,在美国单中心开展,纳入108例18岁及以上、HIV-1控制良好、BMI≥25 kg/m2、有脂肪增生但无1型或2型糖尿病的HIV感染者,1:1随机分配接受32周每周一次皮下司美格鲁肽(8周剂量滴定后1.0 mg用24周)或安慰剂,所有研究人员和参与者保持设盲,分析包括安全性均按意向性治疗原则进行,试验注册号ClinicalTrials.gov NCT04019197。
主要发现
- 32周时,性别校正乘法回归分析显示司美格鲁肽对主要结局腹部内脏脂肪组织有显著效应(β -30.82 cm2,95%CI -50.13至-11.51;变化百分比-30.6%)。
- 腹部皮下脂肪组织β -42.01 cm2(95%CI -75.49至-8.52;变化百分比-11.2%),全身脂肪自然对数-0.21 kg(95%CI -0.33至-0.08;变化百分比-18.9%)。
- 可能相关或相关不良事件的绝对风险差异为0.1111(95%CI -0.0727至0.2869),无统计学显著差异。
- 观察到1例司美格鲁肽相关的4级脂肪酶升高和2例可能相关的胆石症(1级和2级)。
- 每组各有8例(15%)提前退出。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出严重不良事件的潜在风险需在HIV感染者的大规模试验中进一步审视。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HIV-associated lipohypertrophy, which is characterised by an abnormal accumulation of abdominal visceral adipose tissue, remains problematic in people with HIV. Effective interventions are lacking, despite HIV-associated lipohypertrophy carrying a substantial risk of cardiometabolic comorbidity. The primary aim of this trial was to investigate effects of the GLP-1 receptor agonist, semaglutide, on adipose tissue in HIV-associated lipohypertrophy. METHODS: This randomised, double-blind, placebo-controlled phase 2b clinical trial was conducted at a single US site. Key inclusion criteria included people with HIV aged 18 years or older with controlled HIV-1, a BMI of 25 kg/m2 or more, and lipohypertrophy but without type 1 or type 2 diabetes. Participants were randomly assigned 1:1 to receive 32 weeks of once-weekly subcutaneous semaglutide (8-week dose titration and 24 weeks at 1·0 mg) or placebo; all research personnel and participants remained masked to treatment assignment. Primary outcomes were changes at 32 weeks in adipose tissue quantity by body compartment. Analyses, including safety, were performed using intention-to-treat principles. This trial was registered ClinicalTrials.gov (NCT04019197) and is complete. FINDINGS: Between June 10, 2019, and July 28, 2022, 108 participants were randomly assigned to receive semaglutide (n=54) or placebo (n=54). Eight (15%) in each group withdrew prematurely. Significant effects of semaglutide were seen over the 32-week study period in sex-adjusted multiplicative regression analyses for the primary outcome, abdominal visceral adipose tissue (β -30·82 cm2, 95% CI -50·13 to -11·51; % change -30·6%). Decreases were also seen in other key measures, including abdominal subcutaneous adipose tissue (β -42·01 cm2, 95% CI -75·49 to -8·52; % change -11·2%) and total body fat (natural logarithmic -0·21 kg, 95% CI -0·33 to -0·08; % change -18·9%). There were no statistically significant differences in possibly related or related adverse events (absolute risk difference 0·1111, 95% CI -0·0727 to 0·2869); however, one semaglutide-related grade 4 elevated lipase and two possibly related cases of cholelithiasis (grades 1 and 2) were observed. INTERPRETATION: Semaglutide holds promise as an effective treatment for HIV-associated lipohypertrophy. The potential risk of serious adverse events deserves further scrutiny in large trials in people with HIV. FUNDING: National Institutes of Health.
引用
- Eckard AR, Wu Q, Sattar A, et al. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial. Lancet Diabetes Endocrinol. 2024. PMID: 38964353. doi:10.1016/S2213-8587(24)00150-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。